ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2026
The VCPIP1-UBE3A Deubiquitination-Ubiquitination Cascade Contributes to Castration-Resistant Prostate Cancer Progression.
Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
The molecular mechanisms underlying progression from metastatic hormone-sensitive prostate cancer (mHSPC) to metastatic castration-resistant prostate cancer (mCRPC) remain incompletely understood. Paired proteomic profiling of specimens from 10 patients identified VCPIP1 as a candidate regulator, and its clinical relevance was evaluated in an independent cohort of 128 mHSPC patients. Elevated VCPIP1 expression was independently associated with shorter CRPC-free survival. Functional studies demonstrated that VCPIP1 promoted prostate cancer proliferation, migration, invasion, and metastasis in a deubiquitinase activity-dependent manner. Mechanistically, VCPIP1 directly bound UBE3A and stabilized it by removing K48-linked polyubiquitin chains at Lys711, thereby enhancing UBE3A-mediated p53 ubiquitination and proteasomal degradation. Wild-type UBE3A, but not its catalytically inactive C833A mutant, rescued the malignant phenotypes suppressed by VCPIP1 depletion. TP53 knockdown partially reversed these effects in TP53-wild-type LNCaP cells but not in TP53-mutant DU145 cells, indicating a TP53 context-dependent contribution of p53. VCPIP1 depletion also reduced androgen receptor expression in LNCaP cells and enhanced enzalutamide sensitivity in patient-derived organoids. These findings identify a VCPIP1/UBE3A deubiquitination-ubiquitination cascade contributing to CRPC progression and support further investigation of VCPIP1 as a potential prognostic biomarker and therapeutic target.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.